No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

The Ensign Group Acquires Post-Acute Care Campus in Arizona

Editor: What To Know

  • , the parent company of the EnsignTM group of companies, which provide skilled nursing and assisted living services, physical, occupational and speech therapies and other rehabilitative and healthcare services, announced today (August 3, 2020) that it acquired the real estate and operations of a post-acute care retirement campus located in Tempe, AZ.
  •  “We are also very impressed with the talented group of caregivers at these operations and look forward to working together to enhance the clinical outcomes and to take this operation to new heights,” he added.
  •    We have full confidence in our team's ability to add this operation in the midst of a pandemic and look forward to working with our new team,” he added.

The Ensign Group, Inc., the parent company of the EnsignTM group of companies, which provide skilled nursing and assisted living services, physical, occupational and speech therapies and other rehabilitative and healthcare services, announced today (August 3, 2020) that it acquired the real estate and operations of a post-acute care retirement campus located in Tempe, AZ.

The acquisition was effective August 1, 2020.  The acquisition includes Tempe Post Acute, a 62-bed skilled nursing facility and Desert Marigold Senior Living of Tempe a senior living center with 72 assisted living beds and 90 independent living units.

“We are very excited to add this well-respected healthcare campus to our mature operations in the greater Phoenix market” said Barry Port, Ensign’s Chief Executive Officer. “As our first transaction since the COVID pandemic arrived at our door steps, our local leadership team in Arizona has taken extra precautions and have implemented a care plan to meet the needs of patients while closely following local and state guidelines.   We have full confidence in our team’s ability to add this operation in the midst of a pandemic and look forward to working with our new team,” he added.

“This is a unique time to add an operation but our local team of clinical and operational leaders are amongst our most experienced transition teams that have participated in many acquisitions in Arizona,” said Forrest Peterson, President of Bandera Healthcare LLC, Ensign’s Arizona-based subsidiary.  “We are also very impressed with the talented group of caregivers at these operations and look forward to working together to enhance the clinical outcomes and to take this operation to new heights,” he added.

These acquisitions bring Ensign’s growing portfolio to 226 healthcare operations, 24 of which also include assisted living operations, across thirteen states.  Ensign owns the real estate at 92 healthcare operations.  Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, assisted living and other healthcare related businesses throughout the United States.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy